Description
The study shows APOE4 specifically enables sleep deprivation to accelerate Aβ deposition and tau pathology, while APOE3 is protective. The underlying molecular mechanisms driving this isoform-specific vulnerability remain unexplained, limiting targeted therapeutic development.
Gap type: unexplained_observation Source paper: APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition and Aβ-associated tau seeding and spreading. (2023, The Journal of clinical investigation, PMID:37279069)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:27.536473+00:00”, “resolution_summary”: “Resolved by hypothesis h-42f50a4a: Prime Editing Precision Correction of APOE4 to APOE3 in Microglia. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-42f50a4a”, “title”: “Prime Editing Precision Correction of APOE4 to APOE3 in Microglia”, “score”: 0.454, “reason”: “18 token overlaps; entity overlap: apoe, apoe3, apoe4”, “analysis_id”: “SDA-2026-04-03-gap-crispr-neurodegeneration-20260402”, “target_gene”: “APOE”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.826767, “confidence_score”: 0.7, “status”: “promoted”, “pubmed_evidence_ids”: [“39642875”, “40639927”, “41276911”, “41288387”, “41338186”]}, {“id”: “h-6ae3f31128”, “title”: “H6: Epigenetic Reset via APOE4→APOE3 Conversion Reverses Senescence”, “score”: 0.412, “reason”: “8 token overlaps; entity overlap: apoe, apoe3, apoe4”, “analysis_id”: “SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0”, “target_gene”: “APOE; HDAC1; EZH2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.54, “confidence_score”: 0.45, “status”: “proposed”, “pubmed_evidence_ids”: [“24553505”, “29991820”, “30617341”]}, {“id”: “h-9dc6fc2bb1”, “title”: “APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antibodies”, “score”: 0.353, “reason”: “5 token overlaps; entity overlap: apoe, apoe4”, “analysis_id”: “test-hypothesis-fixtures-v1”, “target_gene”: “APOE”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.67, “confidence_score”: 0.8, “status”: “proposed”, “pubmed_evidence_ids”: [“26952885”, “29674595”, “33831375”]}, {“id”: “h-7a3aba26c2”, “title”: “APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology requires proximal validation”, “score”: 0.348, “reason”: “4 token overlaps; entity overlap: apoe, apoe4”, “analysis_id”: “AD-MASTER-PLAN-APOE-20260428030754”, “target_gene”: “APOE”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.604, “confidence_score”: 0.57, “status”: “proposed”, “pubmed_evidence_ids”: []}, {“id”: “h-44195347”, “title”: “APOE4 Allosteric Rescue via Small Molecule Chaperones”, “score”: 0.334, “reason”: “21 token overlaps; entity overlap: apoe, apoe4”, “analysis_id”: “sda-2026-04-01-gap-010”, “target_gene”: “APOE”, “target_pathway”: “Apolipoprotein E lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.764904, “confidence_score”: 0.4, “status”: “debated”, “pubmed_evidence_ids”: [“27097127”, “27365453”, “30335591”, “31367008”, “33891876”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “title”: “This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detrimental in neurodegeneration. This paradox challenges fundamental assumptions about APOE4’s role in AD pathogenesis.\n\nGap type: contradiction\nSource paper: APOE genotype-specific differences in the innate immune response (2021, JAMA Neurology, PMID:33432245)”, “score”: 0.577, “reason”: “8 token overlaps; entity overlap: apoe, apoe4, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.539, “reason”: “10 token overlaps; entity overlap: apoe4, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-193244-89904941_20260416-035819”, “title”: “The abstract identifies APOE4’s primary effect on oligodendrocyte cholesterol metabolism but doesn’t explain the mechanistic pathway. Understanding this mechanism is critical for developing targeted therapeutics that address the root cause rather than downstream effects.\n\nGap type: unexplained_observation\nSource paper: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022, Nature, PMID:34788101)”, “score”: 0.492, “reason”: “9 token overlaps; entity overlap: apoe4, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-193244-89904941”, “quality_score”: 0.69, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-090658-7651c1d2_20260416-033018”, “title”: “The abstract shows p53 is a central regulator of C9orf72-mediated neurodegeneration but doesn’t explain how poly(PR) specifically activates p53. Understanding this upstream trigger mechanism is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). (None, None, PMID:33482083)”, “score”: 0.479, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-090658-7651c1d2”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-083043-759b4c5e_20260416-033650”, “title”: “The study demonstrates that apoE is absolutely required for CAA development, as apoE knockout completely prevents CAA formation. However, the specific molecular pathways by which apoE facilitates Aβ deposition in vessel walls remain unexplained, limiting therapeutic target identification.\n\nGap type: unexplained_observation\nSource paper: Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. (2003, The Journal of neuroscience : the official journal of the Society for Neuroscience, PMID:12944519)”, “score”: 0.441, “reason”: “13 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-083043-759b4c5e”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}